Expand ARWR Menu
ARWR MENU

ARWR Latest Press Releases

-- February 24, 2026 --

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events Business Wire 7:30 AM

-- February 17, 2026 --

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A Globe Newswire 8:30 AM

-- February 5, 2026 --

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results Business Wire 4:05 PM

-- February 4, 2026 --

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 PRNewswire 6:15 PM

-- January 27, 2026 --

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia Business Wire 7:30 AM

-- January 20, 2026 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results Business Wire 4:30 PM

-- January 7, 2026 --

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants Business Wire 11:05 PM
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China Business Wire 7:30 AM

-- January 6, 2026 --

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock Business Wire 6:14 PM
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition Business Wire 7:30 AM

-- January 5, 2026 --

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) Business Wire 7:30 AM

-- December 23, 2025 --

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events Business Wire 7:30 AM

-- December 15, 2025 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- December 8, 2025 --

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies Business Wire 7:30 AM

-- December 2, 2025 --

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia Business Wire 7:30 AM

-- December 1, 2025 --

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences Business Wire 4:00 PM

-- November 25, 2025 --

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results Business Wire 4:00 PM

-- November 24, 2025 --

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics Business Wire 7:30 AM

-- November 18, 2025 --

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) Business Wire 11:52 AM

-- November 6, 2025 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results Business Wire 4:30 PM

-- November 4, 2025 --

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences Business Wire 7:30 AM

-- October 28, 2025 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- October 21, 2025 --

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis Business Wire 7:30 AM
Market Data Delayed 15 Minutes